TD Cowen analyst Brendan Smith reiterated a Buy rating on BioLife Solutions (BLFS – Research Report) today and set a price target of $31.00.
Brendan Smith has given his Buy rating due to a combination of factors that highlight BioLife Solutions’ promising financial outlook and strategic positioning. The company’s initial revenue guidance for FY25, ranging from $95.5 to $99 million, indicates a substantial year-over-year growth, surpassing market expectations. This positive projection is supported by a strong adjusted EBITDA margin, expected to reach the mid-20s in FY25 and potentially expanding into the 30s by late FY26, showcasing the company’s robust core business model.
Furthermore, BioLife Solutions benefits from its biopreservation media, which is integral to numerous approved commercial therapies and is used in a significant portion of cell and gene therapy trials. The company has also implemented strategic price increases with its largest distributors, providing a buffer against future growth risks. These factors, combined with the company’s focus on optimizing its core assets, contribute to a favorable long-term growth trajectory, justifying the Buy rating.
According to TipRanks, Smith is an analyst with an average return of -1.5% and a 36.23% success rate. Smith covers the Healthcare sector, focusing on stocks such as Halozyme, Repligen, and BioLife Solutions.